Targeting the B-cell receptor pathway in diffuse large B-cell lymphoma

被引：45

作者：

Dunleavy, Kieron ^{[1
]}

Erdmann, Tabea ^{[2
,3
]}

Lenz, Georg ^{[2
,3
]}

机构：

[1] George Washington Univ, Canc Ctr, Washington, DC USA

[2] Univ Hosp Munster, Dept Med Hematol Oncol & Pneumol A, Munster, Germany

[3] Cluster Excellence EXC 1003, Cells Mot, Munster, Germany

来源：

CANCER TREATMENT REVIEWS | 2018年 / 65卷

关键词：

B-cell receptor signaling; BTK; P13K; PCNSL; DLBCL; NF-KAPPA-B; PARAFFIN-EMBEDDED TISSUE; NON-HODGKIN-LYMPHOMA; C-BETA INHIBITOR; PHASE-II; GENE-EXPRESSION; MOLECULAR SUBTYPES; R-CHOP; IBRUTINIB; KINASE;

D O I：

10.1016/j.ctrv.2018.01.002

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous diagnostic category with different molecular subtypes defined by distinct gene expression patterns and divergent mechanisms of oncogenic activation. Several studies have suggested an inferior survival for patients of the activated B-cell-like (ABC) versus the germinal center B-cell-like (GCB) DLBCL subtype which has led to increasing interest in investigating pharmacological inhibition of signaling pathways which contribute to lymphomagenesis and that are specifically utilized by ABC DLBCL cells. One of these signaling cascades is the B-cell receptor (BCR) pathway and several approaches in clinical trials to target this cascade have demonstrated promising therapeutic activity. This review discusses our current understanding of the role of BCR signaling in different DLBCL subtypes, including primary central nervous system lymphoma (PCNSL), a subgroup of DLBCL that is particularly dependent on BCR signaling. One specific aim of this review is to highlight novel approaches to therapeutically target BCR signaling in DLBCL. (C) 2018 Elsevier Ltd. All rights reserved.

引用

页码：41 / 46

页数：6

共 70 条

[11] Targetable genetic features of primary testicular and primary central nervous system lymphomas [J].

Chapuy, Bjoern ;

Roemer, Margaretha G. M. ;

Stewart, Chip ;

Tan, Yuxiang ;

Abo, Ryan P. ;

Zhang, Liye ;

Dunford, Andrew J. ;

Meredith, David M. ;

Thorner, Aaron R. ;

Jordanova, Ekaterina S. ;

Liu, Gang ;

Feuerhake, Friedrich ;

Ducar, Matthew D. ;

Illerhaus, Gerald ;

Gusenleitner, Daniel ;

Linden, Erica A. ;

Sun, Heather H. ;

Homer, Heather ;

Aono, Miyuki ;

Pinkus, Geraldine S. ;

Ligon, Azra H. ;

Ligon, Keith L. ;

Ferry, Judith A. ;

Freeman, Gordon J. ;

van Hummelen, Paul ;

Golub, Todd R. ;

Getz, Gad ;

Rodig, Scott J. ;

de Jong, Daphne ;

Monti, Stefano ;

Shipp, Margaret A. .

BLOOD, 2016, 127 (07) :869-881

[12] SYK Inhibition Modulates Distinct PI3K/AKT-Dependent Survival Pathways and Cholesterol Biosynthesis in Diffuse Large B Cell Lymphomas [J].

Chen, Linfeng ;

Monti, Stefano ;

Juszczynski, Przemyslaw ;

Ouyang, Jing ;

Chapuy, Bjoern ;

Neuberg, Donna ;

Doench, John G. ;

Bogusz, Agata M. ;

Habermann, Thomas M. ;

Dogan, Ahmet ;

Witzig, Thomas E. ;

Kutok, Jeffery L. ;

Rodig, Scott J. ;

Golub, Todd ;

Shipp, Margaret A. .

CANCER CELL, 2013, 23 (06) :826-838

[13] Ibrutinib Monotherapy in Relapse or Refractory Primary CNS Lymphoma (PCNSL) and Primary Vitreo-Retinal Lymphoma (PVRL). Result of the Interim Analysis of the iLOC Phase II Study from the Lysa and the French LOC Network [J].

Choquet, Sylvain ;

Houillier, Caroline ;

Bijou, Fontanet ;

Houot, Roch ;

Boyle, Eileen ;

Gressin, Remy ;

Nicolas-Virelizier, Emmanuelle ;

Barrie, Maryline ;

Molucon-Chabrot, Cecile ;

Blonski, Marie ;

El Yamani, Abderrazak ;

Lelez, Marie-Laure ;

Clavert, Aline ;

Coisy, Solene ;

de la Bretonniere, Marjan Ertault ;

Touitou, Valerie ;

Cassoux, Nathalie ;

Boussetta, Sami ;

Broussais, Florence ;

Gelas-Dore, Benedicte ;

Barzic, Noelie ;

Ghesquieres, Herve ;

Hoang-Xuan, Khe ;

Soussain, Carole .

BLOOD, 2016, 128 (22)

[14] Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte [J].

Coiffier, Bertrand ;

Thieblemont, Catherine ;

Van Den Neste, Eric ;

Lepeu, Gerard ;

Plantier, Isabelle ;

Castaigne, Sylvie ;

Lefort, Sophie ;

Marit, Gerald ;

Macro, Margaret ;

Sebban, Catherine ;

Belhadj, Karim ;

Bordessoule, Dominique ;

Ferme, Christophe ;

Tilly, Herve .

BLOOD, 2010, 116 (12) :2040-2045

[15] Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma [J].

Compagno, Mara ;

Lim, Wei Keat ;

Grunn, Adina ;

Nandula, Subhadra V. ;

Brahmachary, Manisha ;

Shen, Qiong ;

Bertoni, Francesco ;

Ponzoni, Maurilio ;

Scandurra, Marta ;

Califano, Andrea ;

Bhagat, Govind ;

Chadburn, Amy ;

Dalla-Favera, Riccardo ;

Pasqualucci, Laura .

NATURE, 2009, 459 (7247) :717-U124

[16] Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma [J].

Crump, Michael ;

Leppa, Sirpa ;

Fayad, Luis ;

Lee, Je Jung ;

Di Rocco, Alice ;

Ogura, Michinori ;

Hagberg, Hans ;

Schnell, Frederick ;

Rifkin, Robert ;

Mackensen, Andreas ;

Offner, Fritz ;

Pinter-Brown, Lauren ;

Smith, Sonali ;

Tobinai, Kensei ;

Yeh, Su-Peng ;

Hsi, Eric D. ;

Tuan Nguyen ;

Shi, Peipei ;

Hahka-Kemppinen, Marjo ;

Thornton, Don ;

Lin, Boris ;

Kahl, Brad ;

Schmitz, Norbert ;

Savage, Kerry J. ;

Habermann, Thomas .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (21) :2484-+

[17] Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles [J].

Cunningham, David ;

Hawkes, Eliza A. ;

Jack, Andrew ;

Qian, Wendi ;

Smith, Paul ;

Mouncey, Paul ;

Pocock, Christopher ;

Ardeshna, Kirit M. ;

Radford, John A. ;

McMillan, Andrew ;

Davies, John ;

Turner, Deborah ;

Kruger, Anton ;

Johnson, Peter ;

Gambell, Joanna ;

Linch, David .

LANCET, 2013, 381 (9880) :1817-1826

[18] Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma [J].

Davis, R. Eric ;

Ngo, Vu N. ;

Lenz, Georg ;

Tolar, Pavel ;

Young, Ryan M. ;

Romesser, Paul B. ;

Kohlhammer, Holger ;

Lamy, Laurence ;

Zhao, Hong ;

Yang, Yandan ;

Xu, Weihong ;

Shaffer, Arthur L. ;

Wright, George ;

Xiao, Wenming ;

Powell, John ;

Jiang, Jian-Kang ;

Thomas, Craig J. ;

Rosenwald, Andreas ;

Ott, German ;

Muller-Hermelink, Hans Konrad ;

Gascoyne, Randy D. ;

Connors, Joseph M. ;

Johnson, Nathalie A. ;

Rimsza, Lisa M. ;

Campo, Elias ;

Jaffe, Elaine S. ;

Wilson, Wyndham H. ;

Delabie, Jan ;

Smeland, Erlend B. ;

Fisher, Richard I. ;

Braziel, Rita M. ;

Tubbs, Raymond R. ;

Cook, J. R. ;

Weisenburger, Dennis D. ;

Chan, Wing C. ;

Pierce, Susan K. ;

Staudt, Louis M. .

NATURE, 2010, 463 (7277) :88-U97

[19] Constitutive nuclear factor κB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells [J].

Davis, RE ;

Brown, KD ;

Siebenlist, U ;

Staudt, LM .

JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 194 (12) :1861-1874

[20] Precision Treatment of Distinct Molecular Subtypes of Diffuse Large B-cell Lymphoma: Ascribing Treatment Based on the Molecular Phenotype [J].

Dunleavy, Kieron ;

Roschewski, Mark ;

Wilson, Wyndham H. .

CLINICAL CANCER RESEARCH, 2014, 20 (20) :5182-5193

← 1 2 3 4 5 6 7 →